Abstract | BACKGROUND: OBJECTIVE: METHODS: One hundred nineteen patients with a 1 to 5-year history of pain attributed to diabetic neuropathy and a score of > or =4 on the Likert pain scale entered the multicenter, randomized, double-blind, placebo-controlled trial. Lacosamide (N=60) titrated from 100 to 400 mg/d or maximum tolerated dose and placebo (N=59) were the trial interventions. Primary efficacy criterion was change in pain score on the 11-point Likert pain scale. Secondary assessments included Short-Form McGill Pain and Short-Form-36 Quality of Life Questionnaires, sleep/activity interference, pain intensity, Patient and Clinical Global Impression of Change, and Profile of Mood. Patients receiving at least 1 dose of medication underwent safety evaluation. RESULTS: Ninety-four patients ( lacosamide 46; placebo 48) completed the trial. Lacosamide had significantly (P=0.039) better pain relief versus placebo (primary outcome). Improvements were also seen in secondary outcome measures. Adverse events occurred in 52 lacosamide and 44 placebo patients. Common adverse events, occurring in > or =5% of patients, were headache ( lacosamide 18%, placebo 22%), dizziness ( lacosamide 15%, placebo 8%), and nausea ( lacosamide 12%, placebo 7%). Five lacosamide and 3 placebo patients withdrew for adverse events. DISCUSSION:
|
Authors | Richard L Rauck, Aziz Shaibani, Victor Biton, Jeff Simpson, Brigitte Koch |
Journal | The Clinical journal of pain
(Clin J Pain)
Vol. 23
Issue 2
Pg. 150-8
(Feb 2007)
ISSN: 0749-8047 [Print] United States |
PMID | 17237664
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetamides
- Analgesics
- Lacosamide
|
Topics |
- Acetamides
(adverse effects, therapeutic use)
- Aged
- Analgesics
(adverse effects, therapeutic use)
- Diabetic Neuropathies
(drug therapy, physiopathology)
- Double-Blind Method
- Drug Eruptions
(etiology)
- Electrocardiography
- Female
- Gastrointestinal Diseases
(chemically induced)
- Headache
(chemically induced)
- Heart
(drug effects, physiopathology)
- Humans
- Lacosamide
- Male
- Middle Aged
- Pain Measurement
- Quality of Life
- Treatment Outcome
|